Give answers for theory exam in PSM for third MBBS level. The answer should be pinned to point and grips important points, no extra information. Give answer based on all available standard resources and remember that the answer should be an examiner pleaser, not so examiner can see the important points easily and highlight important points and all, make a structure so it will be easy for examiner to scan the answers easily and also important point and answer should be writable in a 10 to 12 minutes assuming the speed of writing is moderate. The first topic is human development index. Use mind maps diagram and flow charts where ever. Necessary
human development index PSM community medicine third MBBS exam answer components HDI UNDP
HDI is a composite index measuring achievement in three basic dimensions of human development: Long healthy life + Knowledge + Decent standard of living
- Introduced by UNDP (United Nations Development Programme)
- Values range from 0 to 1 (higher = better development)

DIMENSION INDICATOR(S)
─────────────────────────────────────────────────────
Long & Healthy Life Expectancy at Birth
Life ↓
Life Expectancy Index
─────────────────────────────────────────────────────
Knowledge Mean Years of Schooling (adults ≥25 yrs)
+ Expected Years of Schooling (school-entering age)
↓
Education Index
─────────────────────────────────────────────────────
Decent Standard GNI per capita (PPP US $)
of Living ↓
GNI Index
─────────────────────────────────────────────────────
↓↓↓
[GEOMETRIC MEAN of all 3]
↓
HUMAN DEVELOPMENT INDEX
Dimension Index = (Actual value - Minimum value)
─────────────────────────────────
(Maximum value - Minimum value)
HDI = Geometric Mean of 3 Dimension Indices
= (Life Expectancy Index × Education Index × GNI Index)^(1/3)
Note: For Education, geometric mean of the two sub-indices is taken first, then equation re-applied.
| Dimension | Indicator | Maximum | Minimum |
|---|---|---|---|
| Health | Life expectancy (yrs) | 83.2 | 20 |
| Education | Mean yrs of schooling | 13.2 | 0 |
| Education | Expected yrs of schooling | 20.6 | 0 |
| Education | Combined Education Index | 0.951 | 0 |
| Standard of Living | GNI per capita (PPP $) | 1,08,211 | 163 |
HDI VALUE
│
┌────────────┼────────────┬────────────┐
│ │ │ │
<0.550 0.550-0.699 0.700-0.799 ≥0.800
│ │ │ │
LOW MEDIUM HIGH VERY HIGH
HDI HDI HDI HDI
| Point | Fact |
|---|---|
| Introduced by | UNDP |
| Year first published | 1990 |
| Range | 0 to 1 |
| Calculation method | Geometric mean (NOT arithmetic) |
| Income measure used | GNI per capita in PPP US$ |
| India's rank (2018) | 129th - Medium HDI category |
| Top countries (2018) | Norway, Ireland, Switzerland |
| Bottom countries (2018) | Niger, Central African Republic |
Source: Park's Textbook of Preventive and Social Medicine (reference standard for MBBS PSM)
Iceberg phenomenon of disease
Disease in a community can be compared to an iceberg - only the tip is visible above the waterline, while the vast mass remains hidden below.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
▲ FLOATING TIP (VISIBLE)
| → Symptomatic / Clinical disease
| → What the PHYSICIAN SEES
═══════╪══════════════ WATERLINE ═════════════
| → Apparent ←→ Inapparent demarcation
|
▼ SUBMERGED PORTION (HIDDEN MASS)
→ Subclinical cases
→ Carriers
→ Latent cases
→ Presymptomatic cases
→ Undiagnosed cases
→ What the PHYSICIAN DOES NOT SEE
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
ICEBERG OF DISEASE
│
┌───────────────┴────────────────┐
ABOVE WATERLINE BELOW WATERLINE
(Apparent Disease) (Inapparent Disease)
│ │
┌─────┤ ┌──────────┼──────────────┐
Clinical │ Subclinical Latent Carriers
cases │ infections cases │
│ │ │ │ (e.g., Typhoid,
Mild Severe No symptoms Dormant Hepatitis B)
cases cases yet infection │
Presymptomatic
cases
| Disease | Clinical (Tip) | Subclinical (Hidden) | Ratio |
|---|---|---|---|
| Poliomyelitis | Paralytic cases | Inapparent infections | 1 : 1000 (children) |
| Hypertension | Known cases | Undiagnosed cases | Large hidden portion |
| Diabetes | Diagnosed | Undiagnosed | Huge hidden mass |
| TB | Active cases | Latent TB infection | ~1.7 billion latent globally |
| Anaemia | Known | Undetected | Large hidden portion |
| Mental illness | Treated | Untreated/undiagnosed | Vast hidden mass |
| Malnutrition | Severe/obvious | Mild/moderate | Hidden portion larger |
ABOVE WATERLINE BELOW WATERLINE
───────────────────── ─────────────────────────────
Apparent disease Inapparent disease
Diagnosed cases Undiagnosed / subclinical
Physician sees Physician does NOT see
Morbidity statistics capture These are MISSED in data
SPECTRUM OF DISEASE (Continuous)
├── Subclinical/Inapparent ──── [BELOW waterline = Iceberg base]
├── Mild illness
├── Moderate illness [ABOVE waterline = Iceberg tip]
├── Severe illness
└── Death
The Iceberg concept gives a better picture of sub-clinical to overt disease progression than the spectrum of disease alone.
DETECTION OF HIDDEN DISEASE
│
├── SCREENING PROGRAMMES
│ (mass/selective/multiphasic)
│
├── ACTIVE SURVEILLANCE
│
├── COMMUNITY SURVEYS
│
└── HEALTH CAMPS / OUTREACH
Screening = "search for unrecognized disease by rapidly applied tests in apparently healthy individuals" - this directly addresses the submerged portion of the iceberg.
Epidemiological triad

ENVIRONMENT
/\
/ \
/ \
/ \
/________\
AGENT HOST
Disease occurs when the BALANCE between the three is disturbed Prevention = Break one leg of the triangle
The cause of disease
AGENT
│
┌─────────────────┼──────────────────┐
BIOLOGICAL PHYSICAL CHEMICAL
│ │ │
Bacteria Radiation Poisons/toxins
Viruses Heat/cold Drugs
Fungi Trauma Allergens
Parasites Noise Nutritional
Rickettsia deficiency/excess
Helminths
| Property | Definition |
|---|---|
| Infectivity | Ability to enter and establish in host |
| Pathogenicity | Ability to produce disease in infected host |
| Virulence | Severity of disease produced |
| Antigenicity | Ability to produce immune response |
| Invasiveness | Ability to invade tissues |
| Toxigenicity | Ability to produce toxins |
An organism (usually human/animal) that harbours the disease
HOST FACTORS
│
┌──────────┬──────────┼──────────┬────────────┐
INTRINSIC GENETIC IMMUNO- BEHAV- NUTRI-
FACTORS MAKEUP LOGICAL IOURAL TIONAL
│ │ STATUS FACTORS STATUS
Age Race │ │ │
Sex Sickle cell Immunity Lifestyle Under/over
Ethnicity trait Natural Habits nutrition
HLA type Acquired Occupation
Key determinants: Age, Sex, Genetic constitution, Immunity, Nutrition, Behaviour, Occupation
All external conditions and surroundings of the host that affect disease transmission
| Type | Examples |
|---|---|
| Biological | Vectors (mosquitoes, flies), reservoir hosts, food contamination |
| Physical | Climate, season, geography, temperature, radiation |
| Social/Psychosocial | Poverty, overcrowding, sanitation, education, culture, lifestyle |
EQUILIBRIUM (No disease)
Agent ←──── balanced ────→ Host
↕
Environment
DISEASE OCCURS when:
┌──────────────────────────────────────────┐
│ Agent virulence ↑ │
│ OR Host resistance ↓ │
│ OR Environment favours agent over host │
└──────────────────────────────────────────┘
| Disease | Agent | Host factor | Environment |
|---|---|---|---|
| TB | M. tuberculosis | Malnutrition, immunosuppression | Overcrowding, poverty |
| Malaria | Plasmodium | No immunity, age | Stagnant water, vector habitat |
| Rheumatic fever | Strep pyogenes | Genetic susceptibility | Overcrowding, cold |
| CHD | Multiple | Genetics, age, sex | Sedentary lifestyle, diet |
USES OF EPIDEMIOLOGICAL TRIAD
│
┌────┴────┐
│ │
Understanding Designing
disease INTERVENTIONS
causation │
├── Target AGENT (antibiotics, vaccines)
├── Target HOST (immunization, nutrition)
└── Target ENVIRONMENT (sanitation, vector control)
Key principle: Break ANY ONE leg of the triangle = disease prevented/controlled
Now these are concepts in PSM give all imp points in them revivable in half hour presentable manner
Concept one epidemiology
"The study of the occurrence and distribution of health-related events, states, and processes in specified populations, including the study of the determinants influencing such processes, and the application of this knowledge to control relevant health problems." — IEA Definition (International Epidemiological Association)
EPIDEMIOLOGY
│
┌────────┼────────┐
│ │ │
FREQUENCY DISTRIBUTION DETERMINANTS
│ │ │
Rates & Person Causes/
Ratios Place Risk factors
Time
| Component | What it does |
|---|---|
| Disease Frequency | Rates, ratios - prevalence, incidence, death rates |
| Distribution | Person, Place, Time (3 P's) |
| Determinants | Biological, social, behavioural, economic, political factors |
Ultimate aim: Eliminate/reduce health problems + Promote well-being of society
SCOPE OF EPIDEMIOLOGY
│
┌────┴────┬──────────┬──────────┐
│ │ │ │
Infectious Chronic Accidents Mental
Diseases Diseases Health
│ │
Endemic Non-communicable
Epidemic diseases (CHD, Ca)
│
Health services &
Health-related states
| # | Use | Key Point |
|---|---|---|
| 1 | History of disease | Rise & fall - emerging/disappearing diseases |
| 2 | Community diagnosis | Identify + quantify health problems; epidemiology = "diagnostic tool of community medicine" |
| 3 | Planning & Evaluation | Rational resource allocation; evaluate services by RCTs |
| 4 | Individual risk assessment | Relative risk, attributable risk (e.g., smoker vs non-smoker) |
| 5 | Syndrome identification | Define/refine syndromes by group observation |
| 6 | Natural history of disease | Complete the disease picture beyond hospital data |
| 7 | Searching for causes/risk factors | Identify aetiology → prevention strategies |
Mnemonic: History Community Planning Risk Syndrome Natural Causes = HCP RS NC
EPIDEMIOLOGY
│
┌────┴────────────┐
│ │
DESCRIPTIVE ANALYTICAL
│ │
Person ├── Case-control study
Place ├── Cohort study
Time └── Cross-sectional study
│ │
Generates Tests hypothesis
Hypothesis
+
EXPERIMENTAL
│
├── RCT (gold standard)
├── Field trials
└── Community trials
| Feature | Epidemiology | Clinical Medicine |
|---|---|---|
| Unit of study | Defined population | Individual patient/case |
| Concern | Sick + Healthy both | Sick only |
| Approach | Goes to community | Patient comes to doctor |
| Measure | Rate (cases/population) | Diagnosis + treatment |
| Purpose | Prevention + control | Cure of individual |
Key quote: "Clinician interested in cases; statistician in population; epidemiologist in the RATE (relationship between cases and population)"
RATES
│
├── INCIDENCE RATE = New cases / Population at risk × K
│ (measures risk of disease)
│
├── PREVALENCE RATE = All cases (new+old) / Total population × K
│ │
│ ├── Point prevalence (at one point in time)
│ └── Period prevalence (over a period)
│
└── ATTACK RATE = Cases / Population exposed × 100
(used in outbreaks/epidemics)
RELATIONSHIP:
Prevalence ≈ Incidence × Duration of disease
OBSERVATIONAL EXPERIMENTAL
│ │
┌────┴────┐ ┌──────┴──────┐
DESC. ANALYTIC RCT Field/
│ │ (gold Community
Person ┌──┴──┐ standard) trials
Place │ │
Time Case Cohort
ctrl │
Retrospective Prospective
(exposure?) (disease?)
| Term | Definition |
|---|---|
| Incubation period | Time from exposure to onset of disease |
| Herd immunity | Resistance of a group to a disease when sufficient proportion immune |
| Endemic | Constant presence of a disease in a given area |
| Epidemic | Occurrence of disease in excess of normal expectancy |
| Pandemic | Worldwide epidemic |
| Sporadic | Occasional cases, no connection |
| Attack rate | Incidence rate used in epidemic situations |
DEFINITION = IEA = Occurrence + Distribution + Determinants + Application
AIMS = 3 (Describe + Identify + Provide data)
USES = 7 (Morris)
↓
H-C-P-R-S-N-C
TYPES = Descriptive → Analytical → Experimental
↓ ↓ ↓
Hypothesis Test it Prove it (RCT)
generated
PERSON + PLACE + TIME = 3 variables of descriptive epi
INCIDENCE = new cases (risk measure)
PREVALENCE = all cases (burden measure)
P = I × D
Communicable disease and related nhp in India
A communicable disease is one that can be transmitted from an infected person/animal/environment to a susceptible host, directly or indirectly.
INFECTIOUS RESERVOIR PORT OF MODE OF PORT OF SUSCEPTIBLE
AGENT → OF EXIT → TRANS- → ENTRY → HOST
(pathogen) INFECTION MISSION
│ │ │ │ │ │
Bacteria Human Resp. Direct Resp. No immunity
Virus Animal tract Contact tract Malnutrition
Fungi Environment GIT Indirect GIT Genetic
Parasite Carrier Skin Airborne Skin Age/Sex
Rickettsia GUT Vector Mucosa
Vehicle
Fomite
Break ANY link = Disease prevented
| Type | Examples |
|---|---|
| Direct contact | STDs, Rabies, Ringworm |
| Droplet/Airborne | TB, Measles, COVID, Influenza |
| Faecal-oral (vehicle) | Cholera, Typhoid, Polio, Hepatitis A |
| Vector-borne | Malaria (Anopheles), Dengue (Aedes), Filaria (Culex) |
| Blood/parenteral | HIV, Hepatitis B, C |
| Vertical (mother to child) | HIV, Syphilis, Rubella, HBV |
| Term | Definition |
|---|---|
| Incubation period | Time from exposure to 1st symptom |
| Communicable period | Period when disease can be transmitted |
| Carrier | Infected person who harbours pathogen without symptoms |
| Herd immunity | Group protection when sufficient proportion immune |
| Zoonosis | Disease transmitted from animal to man |
| Notifiable disease | Must be reported to health authorities by law |
CONTROL MEASURES
│
┌────┴──────────────────────┐
│ │
AT SOURCE AT HOST AT ENVIRONMENT
(Agent/Reservoir) │ │
│ Immunization Sanitation
Isolation Chemoprophylaxis Safe water
Quarantine Health education Vector control
Disinfection Nutrition Waste disposal
Treatment Screening
| Programme | Year Started | Target Disease | Key Strategy |
|---|---|---|---|
| NTEP (earlier RNTCP/NTP) | 1962 (NTP), 1997 (RNTCP), renamed NTEP 2020 | Tuberculosis | DOTS |
| NVBDCP | 2003 (renamed from NAMP) | Malaria, Dengue, Filaria, Kala-azar, JE | Vector control + drug treatment |
| NLEP | 1983 | Leprosy | MDT |
| NACP | 1987 | HIV/AIDS | NACO, ART, Prevention |
| NPCB | 1976 | Blindness (Trachoma etc.) | Cataract surgery |
| National Immunization Programme | 1978 (EPI), 1985 (UIP) | Vaccine-preventable diseases | UIP/Mission Indradhanush |
NTP (1962) → RNTCP (1997, DOTS) → End TB Strategy (2014) → NTEP (renamed 2020)
Central TB Division (CTD) - National
↓
State TB Cell (STO) - State
↓
District TB Centre (DTO) - District
↓
Peripheral Health Institutions (PHI)
| Year | Event |
|---|---|
| 1953 | NMCP launched (75 million cases pre-1953) |
| 1958 | Renamed to NMEP (Eradication) |
| 1965 | Cases reduced to 0.1 million ✓ |
| 1970s | Resurgence of malaria |
| 1976 | Cases peaked at 6.46 million ✗ |
| 1999 | Renamed to NAMP |
| 2002 | Renamed to NVBDCP |
| 2016 | National Framework for Malaria Elimination launched |
| 2017 | National Strategic Plan for Malaria Elimination 2017-2022 |
NLCP (1955) → NLEP (1983) → MDT introduced (1982 by WHO)
Goal: Elimination = <1 case per 10,000 population
India declared leprosy eliminated: 2005
| Type | Drugs | Duration |
|---|---|---|
| Paucibacillary (PB) | Dapsone + Rifampicin | 6 months |
| Multibacillary (MB) | Dapsone + Rifampicin + Clofazimine | 12 months |
1986: First HIV case in India
1987: NACP launched
NACO set up (under MoHFW)
| Phase | Year | Focus |
|---|---|---|
| NACP-I | 1992-1999 | Slow down spread of HIV |
| NACP-II | 1999-2006 | Behaviour change, decentralization, NGO involvement |
| NACP-III | 2007-2012 | Halt and reverse epidemic |
| NACP-IV | 2012-2017 | Accelerating response |
| NSP | 2017-2024 | Ending AIDS |
EPI (1978) → UIP (1985) → Mission Indradhanush (2014)
| Vaccine | Disease | Schedule |
|---|---|---|
| BCG | TB | Birth |
| OPV | Polio | 6, 10, 14 weeks + boosters |
| IPV | Polio | 6 & 14 weeks |
| Hepatitis B | Hep B | Birth, 6, 10, 14 weeks |
| DPT | Diphtheria, Pertussis, Tetanus | 6, 10, 14 weeks |
| Hib (Pentavalent) | H. influenzae b | 6, 10, 14 weeks |
| Measles/MR | Measles, Rubella | 9-12 months, 16-24 months |
| JE | Japanese Encephalitis | Selected districts |
| Rotavirus | Rotavirus diarrhoea | Selected states |
| PCV | Pneumococcal | 6, 14 weeks, 9 months |
| TT/Td | Tetanus | 10, 16 years + pregnant women |
DISEASE PROGRAMME YEAR KEY STRATEGY
──────────────────────────────────────────────────
TB NTEP 1962/97 DOTS + End TB
Malaria NVBDCP 1953/02 ACT + LLINs + IRS
Leprosy NLEP 1983 MDT (6/12 months)
HIV/AIDS NACP/NACO 1987 ART + Prevention
Blindness NPCB 1976 Cataract surgery
Filaria NVBDCP - MDA (DEC + Albendazole)
Kala-azar NVBDCP - Elimination by 2023
Dengue/Chik NVBDCP - Vector control (Aedes)
Vaccines UIP 1985 12 antigens covered
Nhp for communicable diseases give them like answer to the question all imp points covered
National Health Programmes are centrally sponsored, goal-directed initiatives by the Government of India to reduce morbidity and mortality from major communicable diseases. Each programme operates through the national health care delivery system from central to peripheral level.
COMMUNICABLE DISEASE NHPs IN INDIA
│
┌─────────┼──────────┬──────────────┬──────────────┐
│ │ │ │ │
NTEP NVBDCP NLEP NACP UIP/NIS
(TB) (Vector- (Leprosy) (HIV/AIDS) (Immunization)
borne)
│
┌──────┼────────┬────────┐
Malaria Dengue Filaria Kala-azar
Chikungunya JE
NTP (1962) → RNTCP (1997, DOTS) → STOP TB (2006) → End TB (2014) → NTEP (renamed 2020)
| # | Component |
|---|---|
| 1 | Political will & administrative commitment |
| 2 | Diagnosis by quality-assured sputum smear microscopy |
| 3 | Adequate supply of quality short-course chemotherapy drugs |
| 4 | Directly Observed Treatment (DOT) |
| 5 | Systematic monitoring & accountability |
Vision: Zero deaths, disease and suffering due to TB (by 2030)
Ministry of Health & Family Welfare
↓
Central TB Division (CTD) - National level
↓
State TB Cell (STO) - State level
↓
District TB Centre (DTO) - District level
↓
Peripheral Health Institutions (PHI)
NVBDCP (2003)
│
├── Malaria
├── Dengue & Chikungunya
├── Lymphatic Filariasis
├── Kala-azar (Visceral Leishmaniasis)
└── Japanese Encephalitis (JE)
| Year | Milestone |
|---|---|
| Pre-1953 | 75 million cases, 0.8 million deaths |
| 1953 | NMCP (National Malaria Control Programme) launched |
| 1958 | Renamed NMEP (Eradication Programme) |
| 1965 | Cases ↓ to 0.1 million |
| 1970s | Resurgence - cases back to 6.46 million (1976) |
| 1999 | Renamed NAMP |
| 2002 | Renamed NVBDCP |
| 2005 | RDT (Rapid Diagnostic Test) introduced |
| 2006 | ACT (Artemisinin Combination Therapy) introduced for Pf resistance |
| 2009 | LLINs (Long-Lasting Insecticidal Nets) introduced |
| 2016 | National Framework for Malaria Elimination launched |
| 2017 | National Strategic Plan for Malaria Elimination 2017-2022 |
ANTI-MALARIA MEASURES
│
┌────┴────┬──────────────┐
│ │ │
PARASITE VECTOR HOST
│ │ │
Diagnosis IRS (DDT/ Chemoprophylaxis
RDT/Smear Malathion) Presumptive
ACT/CQ Larvicides treatment
treatment LLINs IEC
Biological
control
NLCP (1955) → NLEP (1983) → WHO MDT introduced (1982) → Elimination achieved (2005)
Elimination = <1 case per 10,000 population at national level India achieved elimination at national level: 2005
| Type | Drugs | Duration |
|---|---|---|
| PB (Paucibacillary) | Rifampicin + Dapsone | 6 months |
| MB (Multibacillary) | Rifampicin + Dapsone + Clofazimine | 12 months |
MDT = Monthly supervised + daily unsupervised doses
LEPROSY
│
├── PB (1-5 skin patches, smear negative)
│ → Tuberculoid (TT), Borderline Tuberculoid (BT)
│
└── MB (>5 skin patches, smear positive)
→ Borderline (BB), Borderline Lepromatous (BL), Lepromatous (LL)
1986: First HIV case in India
1987: NACP launched → NACO set up
1992: NACP-I → 1999: NACP-II → 2007: NACP-III → 2012: NACP-IV → 2017: NSP 2017-2024
| Phase | Year | Focus |
|---|---|---|
| NACP-I | 1992-1999 | Slow down HIV spread; surveillance |
| NACP-II | 1999-2006 | Behaviour change; decentralisation; NGO involvement |
| NACP-III | 2007-2012 | Halt & reverse epidemic; ART scale-up |
| NACP-IV | 2012-2017 | Accelerate response; concentrate on high-risk groups |
| NSP | 2017-2024 | Ending AIDS; 90-90-90 targets |
National AIDS Control Organization (NACO)
- Under Ministry of Health & Family Welfare
↓
State AIDS Control Societies (SACS)
↓
District AIDS Prevention & Control Units (DAPCU)
90% of people with HIV know their status
→ 90% of diagnosed on treatment
→ 90% of treated virally suppressed
EPI launched by WHO (1974) → EPI India (Jan 1978) → UIP launched (Nov 19, 1985)
Dedicated to memory of Smt. Indira Gandhi
| Vaccine | Disease | Schedule |
|---|---|---|
| BCG | TB | Birth |
| OPV | Polio | Birth, 6, 10, 14 wks; 16-18 months; 5 yrs |
| IPV | Polio | 6 & 14 weeks |
| Hep B | Hepatitis B | Birth, 6 wks, 14 wks |
| Pentavalent | DPT + HepB + Hib | 6, 10, 14 weeks |
| Measles/MR | Measles, Rubella | 9-12 months; 16-24 months |
| Rotavirus | Diarrhoea | 6, 10, 14 weeks (selected states) |
| PCV | Pneumonia | 6 wks, 14 wks, 9 months |
| JE | Japanese Encephalitis | 9-12 months (endemic districts) |
| TT | Tetanus | 10 yrs, 16 yrs + Pregnant women |
Reach all unvaccinated/partially vaccinated children under 2 years Target: Full immunization coverage → 90%
State Vaccine Store → Regional/Divisional Store → District Store
→ CHC/PHC → Sub-Centre → Village (field worker/ANM)
| Programme | Started | Target | Key Strategy | Goal |
|---|---|---|---|---|
| NTEP | 1962/1997/2020 | TB | DOTS | Elimination by 2025 |
| NVBDCP | 2003 | Malaria, Dengue, Filaria, KA, JE | IRS, ACT, MDA, LLINs | Malaria elimination 2027 |
| NLEP | 1983 | Leprosy | MDT (6/12 months) | Elimination (achieved 2005) |
| NACP/NACO | 1987 | HIV/AIDS | ART, ICTC, TI | 90-90-90 |
| UIP | 1985 | Vaccine-preventable | 12 antigens; cold chain | Universal coverage |